Drug Development – Page 6

Servier and Google Cloud Extend Partnership to Accelerate AI-Powered Drug Development

11 months ago talkbio0Tagged Artificial Intelligence, digital transformation, Drug Development, generative, Google Cloud, Pharmaceutical Research, R&D, Servier, therapeutic solutions

Servier, Google Cloud, AI, drug development, pharmaceutical research, digital transformation, R&D, generative AI, gen AI, therapeutic solutions.

Denali and AbbVie’s ALS Candidates Fail Phase 2/3 Trials, Highlighting Challenges in ALS Research

11 months ago talkbio0Tagged AbbVie, Amyotrophic Lateral Sclerosis, Calico Life Sciences, Clinical Trials, Denali, DNL343, Drug Development, fosigotifator, HEALEY

ALS, Denali Therapeutics, AbbVie, Calico Life Sciences, HEALEY ALS Platform Trial, DNL343, fosigotifator, amyotrophic lateral sclerosis, clinical trials, drug development

Eli Lilly and Alchemab Therapeutics Collaborate on Novel ALS Therapies

11 months ago talkbio0Tagged Alchemab, Amyotrophic Lateral Sclerosis, Drug Development, Eli, Eli Lilly, Neurodegenerative Disorders, Therapeutic Antibodies

Eli Lilly, Alchemab Therapeutics, ALS, Therapeutic Antibodies, Neurodegenerative Disease, Drug Development

Novo Nordisk and Valo Health Expand AI-Driven Collaboration to Develop Novel Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease

11 months ago talkbio0Tagged Artificial Intelligence, biotech, Cardiovascular Diseases, Computational Technique, Diabetes, Drug Development, Nordisk, Obesity, Valo Health

Novo Nordisk, Valo Health, AI, Obesity, Type 2 Diabetes, Cardiovascular Disease, Drug Development, Computational Biotech

Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform

11 months ago talkbio0Tagged Alloys, AntiClastic Antisense Platform, Blood - brain barrier anatomy, Clinical Nurse Specialists, Drug Development, Genetic Medicine, RNA, sanofi

Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine

FDA Introduces New Guidance on AI for Drug Approval Submissions in 2025

11 months ago talkbio0Tagged Advice, Artificial Intelligence, Drug Approval, Drug Development, Medical Devices, regulatory decision-making, United States Food and Drug Administration

FDA, AI, drug approval, guidance, regulatory decision-making, medical devices, artificial intelligence, drug development

Valo Health Suspends Development of OPL-0401, a ROCK Inhibitor for Diabetic Retinopathy, Following Phase 2 Study Results

11 months ago talkbio0Tagged Clinical Trials, Diabetic Retinopathy, Drug Development, Inhibitor, OPL-0401, Phase 2 Clinical Trials, ROCK, Valo Health

Valo Health, OPL-0401, ROCK Inhibitor, Diabetic Retinopathy, Phase 2 Study, Clinical Trials, Drug Development

KdT Ventures Launches New Biotech Startup to Develop NGM Bio’s Rare Disease Drug Candidate NGM313

12 months ago talkbio0Tagged Bio, Biotechnology, Drug Development, KdT, NGM, NGM313, Phase 2 trial, Ventures

KdT Ventures, NGM Bio, NGM313, Rare Disease, Biotechnology, Drug Development, Phase 2 Trial

UCB and Novartis Discontinue Development of Parkinson’s Disease Drug After Phase 2 Failure

12 months ago talkbio0Tagged Drug Development, Novartis, Parkinson 's disease, Phase 2 Failure, UCB

UCB, Novartis, Parkinson’s disease, drug development, Phase 2 failure, UCB0599, UCB7853

Biomarker Data’s Potential to Expedite Approval of Edgewise’s Dystrophy Drug

12 months ago talkbio0Tagged Becker, Biological Markers, Drug Development, regulatory approval

Biomarkers, drug development, Edgewise Therapeutics, Becker muscular dystrophy, regulatory approval